SATB2 Promotes Radiation Resistance of Esophageal Squamous Cell Carcinoma by Regulating Epithelial-to-mesenchymal Transition Via the Wnt/β-catenin Pathway

Overview

Journal Front Oncol

Specialty Oncology

Date 2025 Mar 13

PMID 40078194

Authors

Chen Lin

Youyi Wu

Yuchen Qian

Jiayi Li

Youdi He

Huang Yu

Congying Xie

Huafang Su

Affiliations

Soon will be listed here.

Abstract

Purpose: Radioresistance remains a predominant factor contributing to local recurrence in esophageal squamous cell carcinoma (ESCC). SATB2, as a transcriptional co-gene, may affect the radioresistance of cancer cells. Consequently, this study aims to elucidate the mechanism by which SATB2 modulates radiotherapy resistance in esophageal cancer.

Methods: We identified highly expressed genes associated with radioresistance in ESCC using the MSigDB database and conducted survival correlation analysis. A radioresistant esophageal squamous cell carcinoma cell line (KYSE150R) was established using the gradient dose method, and RT-qPCR was used to detect the expression of SATB2 in KYSE150 and KYSE150R cells. CCK-8, Transwell, colony formation assay, and cell scratching were performed to determine and evaluate cell proliferation, cell migration, and cell invasion. Furthermore, the expression levels of mRNA and protein were correlated using WB and RT-qPCR. Mitochondrial membrane potential and apoptosis detection kits were used to evaluate the level of apoptosis. Finally, a mouse subcutaneous xenograft tumor model was employed to elucidate the role of SATB2 on the radiotherapy resistance of ESCC .

Results: Bioinformatics analysis indicated that SATB2 is linked to increased drug resistance in esophageal cancer. The results demonstrated that suppression of SATB2 decelerates cell proliferation and migration, accelerates apoptosis, inhibits the GSK-3β (Ser9) phosphorylation, and reduces β-catenin and target gene C-myc. The addition of the Wnt/β-catenin signaling pathway agonist (CHIR-99021) reversed these effects. Xenograft studies in mice revealed that knockdown of SATB2 reduced ESCC radioresistance.

Conclusion: We concluded that SATB2 may dysregulate the Wnt/β-catenin pathway, thereby facilitating EMT progression and conferring radioresistance.

References

Sato S, Maekawa R, Tamura I, Shirafuta Y, Shinagawa M, Asada H . SATB2 and NGR1: potential upstream regulatory factors in uterine leiomyomas. J Assist Reprod Genet. 2019; 36(11):2385-2397. PMC: 6885490. DOI: 10.1007/s10815-019-01582-y. View

Li L, Wang X, Jiang M, Li L, Wang D, Li Y . Advancements in a novel model of autophagy and immune network regulation in radioresistance of cancer stem cells. Biomed Pharmacother. 2024; 179:117420. DOI: 10.1016/j.biopha.2024.117420. View

Gao J, Meng Y, Ge X, Hou C, Zhu Q, Wang Y . SATB2 overexpression promotes oral squamous cell carcinoma progression by up-regulating NOX4. Cell Signal. 2021; 82:109968. DOI: 10.1016/j.cellsig.2021.109968. View

Gu J, Wang G, Liu H, Xiong C . SATB2 targeted by methylated miR-34c-5p suppresses proliferation and metastasis attenuating the epithelial-mesenchymal transition in colorectal cancer. Cell Prolif. 2018; 51(4):e12455. PMC: 6528935. DOI: 10.1111/cpr.12455. View

Song P, Gao Z, Bao Y, Chen L, Huang Y, Liu Y . Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy. J Hematol Oncol. 2024; 17(1):46. PMC: 11184729. DOI: 10.1186/s13045-024-01563-4. View

Roy S, Shrivastava A, Srivastav S, Shankar S, Srivastava R . SATB2 is a novel biomarker and therapeutic target for cancer. J Cell Mol Med. 2020; 24(19):11064-11069. PMC: 7576221. DOI: 10.1111/jcmm.15755. View

Berg K, Schaeffer D . SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls. Arch Pathol Lab Med. 2017; 141(10):1428-1433. DOI: 10.5858/arpa.2016-0243-RS. View

Martinez-Campa C, Alvarez-Garcia V, Alonso-Gonzalez C, Gonzalez A, Cos S . Melatonin and Its Role in the Epithelial-to-Mesenchymal Transition (EMT) in Cancer. Cancers (Basel). 2024; 16(5). PMC: 10931174. DOI: 10.3390/cancers16050956. View

Goncharov A, Vashakidze N, Kharaishvili G . Epithelial-Mesenchymal Transition: A Fundamental Cellular and Microenvironmental Process in Benign and Malignant Prostate Pathologies. Biomedicines. 2024; 12(2). PMC: 10886988. DOI: 10.3390/biomedicines12020418. View

10.

Li C, Furth E, Rustgi A, Klein P . When You Come to a Fork in the Road, Take It: Wnt Signaling Activates Multiple Pathways through the APC/Axin/GSK-3 Complex. Cells. 2023; 12(18). PMC: 10528086. DOI: 10.3390/cells12182256. View

11.

Puhr H, Prager G, Ilhan-Mutlu A . How we treat esophageal squamous cell carcinoma. ESMO Open. 2023; 8(1):100789. PMC: 9958251. DOI: 10.1016/j.esmoop.2023.100789. View

12.

Sheikh M, Roshandel G, McCormack V, Malekzadeh R . Current Status and Future Prospects for Esophageal Cancer. Cancers (Basel). 2023; 15(3). PMC: 9913274. DOI: 10.3390/cancers15030765. View

13.

Saitoh M . Epithelial-Mesenchymal Transition by Synergy between Transforming Growth Factor-β and Growth Factors in Cancer Progression. Diagnostics (Basel). 2022; 12(9). PMC: 9497767. DOI: 10.3390/diagnostics12092127. View

14.

Kucuksayan H, Ozes O, Akca H . Downregulation of SATB2 is critical for induction of epithelial-to-mesenchymal transition and invasion of NSCLC cells. Lung Cancer. 2016; 98:122-129. DOI: 10.1016/j.lungcan.2016.05.032. View

15.

Pawlicka M, Gumbarewicz E, Blaszczak E, Stepulak A . Transcription Factors and Markers Related to Epithelial-Mesenchymal Transition and Their Role in Resistance to Therapies in Head and Neck Cancers. Cancers (Basel). 2024; 16(7). PMC: 11010970. DOI: 10.3390/cancers16071354. View

16.

Bhuvanalakshmi G, Basappa , Rangappa K, Dharmarajan A, Sethi G, Kumar A . Breast Cancer Stem-Like Cells Are Inhibited by Diosgenin, a Steroidal Saponin, by the Attenuation of the Wnt β-Catenin Signaling via the Wnt Antagonist Secreted Frizzled Related Protein-4. Front Pharmacol. 2017; 8:124. PMC: 5357646. DOI: 10.3389/fphar.2017.00124. View

17.

Hayat R, Manzoor M, Hussain A . Wnt signaling pathway: A comprehensive review. Cell Biol Int. 2022; 46(6):863-877. DOI: 10.1002/cbin.11797. View

18.

Wang Y, Jiang D, Hu S, Zhao L, Wang L, Yang M . Suppresses Colorectal Carcinoma Aggressiveness by Inhibiting SATB2-Dependent Transcription and Epithelial-Mesenchymal Transition. Cancer Res. 2019; 79(14):3542-3556. DOI: 10.1158/0008-5472.CAN-18-2900. View

19.

Yuan L, Cao J, Hu M, Xu D, Li Y, Zhao S . Bone marrow mesenchymal stem cells combined with estrogen synergistically promote endometrial regeneration and reverse EMT via Wnt/β-catenin signaling pathway. Reprod Biol Endocrinol. 2022; 20(1):121. PMC: 9377128. DOI: 10.1186/s12958-022-00988-1. View

20.

Lee S, Jeong E, Ju M, Jeon H, Kim M, Kim C . Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer. 2017; 16(1):10. PMC: 5282724. DOI: 10.1186/s12943-016-0577-4. View